Statistics for Xeris Pharmaceuticals (id:8127 XERS)

Valuation metrics

Market cap

453.21M

Enterprise value

657.75M

Trailing P/E (ttm)

-6.87

Forward P/E

-13.82

PEG ratio

-13.82

Price/Sales (ttm)

2.42

Price/Book (mrq)

-16.26

Enterprise Value/Revenue

3.51

Enterprise Value/EBITDA

-19.89

Overview

Shares outstanding

149.08M

Float

142.50M

Shares short

11.37M

% Held by insiders

0.04%

% Held by institutions

0.44%

Average volume (10 days)

2.31M

Average volume (90 days)

Price summary

52-Week low

1.69

52-Week high

3.64

52-Week change

40.45%

Beta

1.28

50-Day moving average

3.03

200-Day moving average

2.50

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-33.68%

Operating margin

-23.76%

Operational effectiveness

Return on assets

-8.70%

Return on equity

917.94%

Income statement

Revenue (ttm)

1.30

Revenue per share (ttm)

1.30

Quarterly revenue growth (yoy)

Gross profit (ttm)

135.27M

EBITDA

-33,063,000.00

Net income to common (ttm)

-63,113,000.00

Diluted EPS (ttm)

-0.43

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

69.40M

Total cash per share (mrq)

0.47

Total debt (mrq)

270.96M

Total Debt/Equity (mrq)

-9.57

Current ratio (mrq)

178.90%

Book value per share (mrq)

-0.19

Cash flow

Cash flow statement

-31,485,000.00

Levered free cash flow (LFCF)

-30,717,750.00